Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
- CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company's virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits strong antiviral activity against the highly pathogenic H5N1 avian influenza A strain (A/Texas/37/2024).
- 05/29/2025
|
Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference
- BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference on Thursday, June 5, 2025 at 12:00 p.m.
- 05/28/2025
|
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
- 05/15/2025
|
Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
- BOTHELL, Wash., April 24, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its investigative drug candidate CDI-988 was shown to bind to the highly conserved region of the GII.17 protease with excellent potency, similar to that shown across a range of GII.4 norovirus variants that had been the dominant worldwide strains until this year. The high resolution GII.17 protease crystal structures used in determining CDI-988's activity were obtained using the Company's proprietary structure-based platform technology. Cocrystal plans to initiate a human norovirus challenge study in 2025 in the U.S. to evaluate CDI-988 as a potential prevention and treatment of norovirus infection.
- 04/24/2025
|
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
- BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on Wednesday, April 23, 2025 at 3:00 p.m.
- 04/16/2025
|
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
- 03/31/2025
|
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025
- BOTHELL, Wash., March 06, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
- 03/06/2025
|
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
- U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday.
- 12/31/2024
|
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
- BOTHELL, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral influenza PB2 inhibitor CDI-42344 due to unexpectedly low influenza infection among study participants who were challenged with a H3N2 viral strain. This randomized, double-blind, placebo-controlled Phase 2a study is evaluating the safety, tolerability, pharmacokinetics (PK), antiviral activity and clinical measurements of CC-42344 at a single site in the United Kingdom.
- 12/31/2024
|
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
- BOTHELL, Wash., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .'s (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September.
- 08/19/2024
|
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
- NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.
- 08/15/2024
|
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
- After reaching an important support level, Cocrystal Pharma, Inc. (COCP) could be a good stock pick from a technical perspective. COCP recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
- 06/07/2024
|
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- BOTHELL, Wash., May 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
- 05/13/2024
|
Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
- BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344. CC-42344 is a new class of antiviral treatment designed to effectively block an essential step in the viral replication and transcription of pandemic and seasonal influenza A, and was discovered using the Company's proprietary structure-based drug discovery platform technology.
- 05/01/2024
|
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
- BOTHELL, Wash., March 28, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.
- 03/28/2024
|
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
- Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA) regarding CC-42344 as a potential oral treatment for pandemic and seasonal influenza A.
- 03/19/2024
|
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
- LOS ANGELES, CA / ACCESSWIRE / March 5, 2024 / Planet MicroCap today published a new Video Interview with Jim Martin, Co-CEO and CFO, from Cocrystal Pharma, Inc. (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses, according to the company's website (see here: https://www.cocrystalpharma.com/). Click the following link to watch the Video Interview: Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts You can follow Planet MicroCap on TWITTER, LINKEDIN, YOUTUBE Please review important disclosures on our website at: https://snn.network/terms-of-use About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses.
- 03/05/2024
|
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
- BOTHELL, Wash., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dosed with oral CC-42344 treatment.
- 12/06/2023
|
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
- BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal influenza A strains at the World Vaccine Congress West Coast. Cocrystal has initiated a Phase 2a human challenge trial with oral CC-42344 in the UK in subjects infected with influenza A, and plans to begin a Phase 1 trial with inhaled CC-42344 as a potential influenza A treatment and prophylaxis in Australia in the first half of 2024.
- 11/29/2023
|
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
- BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference on Monday, December 4 at 1:30 p.m. Eastern time. The conference is being held December 3-5 at the College of Business Executive Education Building at Florida Atlantic University in Boca Raton, Fla.
- 11/27/2023
|
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
- BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces that President and co-CEO Sam Lee, PhD will discuss progress in developing the novel, broad-spectrum PB2 inhibitor CC-42344 in an oral presentation, “Taking a new route: Development of novel inhaled and oral influenza antiviral, CC-42344” at the World Vaccine Congress West Coast on Tuesday, November 28, 2023 at 3:20 p.m. Pacific Time. The conference is being held November 27-30 at the Santa Clara Convention Center in Santa Clara, Calif.
- 11/09/2023
|
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
- BOTHELL, Wash., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human challenge trial with its broad-spectrum, oral PB2 inhibitor CC-42344 as a potential treatment for pandemic and seasonal influenza A. Cocrystal expects to begin treating influenza-infected subjects in this trial during the fourth quarter of 2023.
- 10/31/2023
|
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
- BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel small molecule antiviral therapeutics, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Cocrystal presentation will be available on the IR Calendar section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time.
- 09/05/2023
|
Penny Stocks To Buy Now? 4 Under $3 To Watch This Week
- Penny stocks to watch this week under $3. The post Penny Stocks To Buy Now?
- 04/10/2023
|
Cocrystal Pharma to Participate in Two Investor Conferences in November
- BOTHELL, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investor conferences as follows: 2022 BioFlorida Annual Conference: James Martin, CFO and interim co-CEO, will participate in a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on Thursday, November 3… The post Cocrystal Pharma to Participate in Two Investor Conferences in November appeared first on DKODING...
- 11/02/2022
|
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
- BOTHELL, Wash., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces it has been granted European patent EP3866778 titled “Combinations Of Inhibitors of Influenza Virus Replication,” which covers the Company’s broad-spectrum oral PB2 inhibitor CC-42344 in combination with approved influenza antiviral drugs including Tamiflu®, Xofluza® or Favipiravir. Cocrystal recently announced the completion… The post Cocrystal Pharma Granted European Patent Covering Oral Antiviral...
- 11/01/2022
|
Cocrystal Pharma to Present at the LD Micro Main Event XV
- BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present a company overview of their antiviral programs and clinical trials at the LD Micro Main Event XV on Wednesday, October 26 at 3:30 p.m. Pacific time (6:30 p.m. Eastern time). The… The post Cocrystal Pharma to Present at the LD Micro Main Event XV appeared first on DKODING...
- 10/19/2022
|
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
- BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present data from the Company’s Phase 1 influenza A clinical trial with CC-42344 at the World Antiviral Congress 2022 on Friday, December 1, 2022 at 11:10 a.m. Pacific time. The conference is… The post Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022 appeared first on DKODING...
- 10/13/2022
|
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
- BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development as an oral treatment for SARS-CoV-2, the virus that causes COVID-19. CDI-988 targets a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for… The post Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 appeared first on DKODI...
- 10/11/2022
|
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
- BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held… The post Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference appeared first on DKODING...
- 10/05/2022
|
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
- BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at the Wyndham Grand Hotel in Jupiter, Fla.
- 10/05/2022
|
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
- BOTHELL, Wash., Oct. 03, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its Board of Directors has approved a 1-for-12 reverse stock split of the Company’s common stock. Cocrystal’s common stock is expected to begin trading on a split-adjusted basis at commencement of trading on Tuesday, October 11,… The post Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split appeared first on DKODING...
- 10/03/2022
|
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
- BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 10:00 a.m. Eastern Time. The hybrid in-person and virtual conference is being held at the Fontainebleau Miami Beach Hotel in Miami Beach.
- 05/18/2022
|
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
- BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at the hybrid in-person and virtual Life Science Innovation Northwest 2022 (LSINW) Conference being held April 20-21, 2022 at the Washington State Convention Center in Seattle. Dr. Lee's presentation is scheduled during the Neuroscience & Pharmaceuticals segment on Wednesday, April 20 at 3:25 p.m. Pacific time.
- 04/19/2022
|
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
- Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A. The ongoing Phase 1 trial, designed to evaluate CC-42344 administered in single-ascending and multiple-.
- 04/12/2022
|
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
- CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication.
- 01/27/2022
|
4 Biotech Penny Stocks to Watch With New Catalysts
- These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/08/2021
|
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates
- Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/15/2021
|
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know
- Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/08/2021
|
Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19
- Cocrystal Pharma Inc (NASDAQ: COCP) has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19. FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205.
- 11/01/2021
|
Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021
- BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces that management will present at the Dawson James 2021 Small Cap Growth Conference on Thursday, October 21, 2021 at 2:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at the Wyndham Grand Hotel in Jupiter, Fla.
- 10/14/2021
|
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
- BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces receipt of clearance from an Australian Human Research Ethics Committee (HREC) to initiate a Phase 1 trial with its orally administered PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A.
- 10/06/2021
|
5 Best Penny Stocks To Buy Right Now According To Insiders
- 5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/25/2021
|
Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates
- Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/16/2021
|
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q2 Earnings? What You Should Know
- Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2021
|
Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Variants
- Cocrystal Pharma Inc (NASDAQ: COCP) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants. "Our next steps are to scale-up synthesis and manufacture active pharmaceutical ingredient (API) to support Investigational New Drug (IND)-enabling studies to advance CDI-45205 into clinical trials," said James Martin, CFO, and interim co-CEO.
- 07/29/2021
|
COCP Stock Increases Over 15% Pre-Market: Why It Happened
- The stock price of Cocrystal Pharma Inc (NASDAQ: COCP) increased by over 15% pre-market. This is why it happened.
- 07/29/2021
|
8 Hot Penny Stocks That You Should Add to Your July Watchlist
- With July in full swing, here's 8 penny stocks that investors are watching right now The post 8 Hot Penny Stocks That You Should Add to Your July Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/02/2021
|
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
- BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1 clinical development of CC-42344 in the third quarter of 2021.
- 06/23/2021
|
7 Hot Penny Stocks to Watch That Are Trending Right Now
- Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/20/2021
|
Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains
- Cocrystal Pharma Inc (NASDAQ: COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party laboratory contracted by Cocrystal conducted in vitro studies evaluating the antiviral activity of CDI-45205 and its analogs in VeroE6-eGFP cells infected with SARS-CoV-2 (Wuhan strain), the U.K. variant (B.1.1.7), and the South African variant (B.1.351).
- 06/14/2021
|
COCP Stock Price: Over 10% Increase Pre-Market Explanation
- The stock price of Cocrystal Pharma Inc (NASDAQ: COCP) increased by over 10% pre-market. These are the details.
- 06/14/2021
|
Cocrystal's Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants
- BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, announces that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants.
- 06/14/2021
|
Cocrystal Pharma's Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
- BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management's participation in the Noble Capital Markets C-Suite Interview Series is now available online. During the 30-minute video int e rview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer, Cocrystal discussed its antiviral drug-discovery and development work and provided program updates.
- 06/09/2021
|
Target Highly Promising Antiviral Therapeutics with Cocrystal Pharma
- A buying opportunity is here as COCP stock is down, even as Cocrystal makes progress in developing a potentially lifesaving antiviral drug. The post Target Highly Promising Antiviral Therapeutics with Cocrystal Pharma appeared first on InvestorPlace.
- 05/27/2021
|
7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts
- Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appeared first on InvestorPlace.
- 05/12/2021
|
Cocrystal Pharma Announces Closing of $40 Million Bought Deal
- BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, today announced the closing of its previously announced public offering of 26,000,000 shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriting discounts and commissions.
- 05/07/2021
|
Rookie Traders Get Crushed By Cocrystal Pharma Stock
- The trading in biotechnology company Cocrystal Pharma, Inc. (NASDAQ: COCP) is a good example of how inexperienced traders can lose a lot of money. What Happened: Cocrystal closed Tuesday at $2.14, a gain of over 70%.
- 05/05/2021
|
Cocrystal stock pulls back sharply after stock offering priced to the public at a deep discount
- Shares of Cocrystal Pharma Inc. plunged 28.3% in active premarket trading, after the biotechnology company announced a $40 million common stock offering. The company announced the offering Tuesday's closing bell, after the stock rocketed 72.6% on Tuesday after the announcement that "progress" was made in the development of the company's antiviral drug candidates targeting coronaviruses including those that cause COVID-19.
- 05/05/2021
|
Cocrystal Pharma Shares Plunge On $40M Equity Raise At 28% Discount
- Cocrystal Pharma Inc (NASDAQ: COCP) has entered into an underwriting agreement with H.C. Wainwright & Co LLC, under which the underwriter has agreed to purchase 26 million shares at $1.54 per share.
- 05/05/2021
|
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
- BOTHELL, Wash., May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 26,000,000 shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about May 7, 2021, subject to satisfaction of customary closing conditions.
- 05/04/2021
|
Cocrystal stock doubles on massive volume a day after progress announced on coronavirus drug candidates
- Shares of Cocrystal Pharma Inc. more than doubled on massive record volume in afternoon trading Tuesday, a day after the biotechnology company said it has made "progress" in developing antiviral drug candidates that target coronaviruses, including those that cause COVID-19. Trading volume skyrocketed to 559.5 million shares, compared with the full-day average of about 832,300 shares.
- 05/04/2021
|
Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today
- Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.
- 05/04/2021
|
COCP Stock: From $1.24 to $1.98 (59.68% Increase) Pre-Market Explanation
- The stock price of Cocrystal Pharma, Inc. (Nasdaq: COCP) increased 59.68% pre-market as it went from $1.24 to $1.98. This is why it happened.
- 05/04/2021
|
Cocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral Candidate
- Cocrystal Pharma Inc (NASDAQ: COCP) has announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 program with additional antiviral compounds for development, apart from CDI-45205. The company said that it had designed new chemical scaffolds to improve in vitro potency and pharmacokinetic properties.
- 05/03/2021
|
Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference
- BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021. A webcast of Cocrystal's presentation has been pre-recorded and is available on the Company's website here .
- 03/09/2021
|
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference [UPDATED]
- BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.
- 03/02/2021
|
Cocrystal Pharma (COCP) Jumps: Stock Rises 7.3%
- Cocrystal Pharma (COCP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- 01/21/2021
|
Cocrystal Pharma Presentation at the reimagine Health Research Symposium Features Overview of Platform Technology and Four Antiviral Case Studies
- BOTHELL, Wash., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, provides the following summary of today's upcoming presentation by Cocrystal President Sam Lee, Ph.D. at the virtual 3rd Annual reimagine Health Research Symposium, University of Arizona College of Medicine. A live webcast of Dr. Lee's presentation, titled “Application of Structure-Based Drug Design Platform Technology for Developing Broad Spectrum, COVID-19, Influenza, and HCV Antivirals,” will be available at 9:50 a.m. Pacific time (12:50 p.m. Eastern time) by registering here . Dr. Lee's presentation will be available on the Cocrystal website here beginning Friday, January 22, 2021.
- 01/21/2021
|
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement
- Program advances within the agreement's initial two-year timeframe
- 01/19/2021
|
Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021
- BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces that management will present at NobleCon17, Noble Capital Markets' 17th Annual Investor Conference on Tuesday, January 19, 2021 at 2:15 p.m. Eastern time (11:15 a.m. Pacific time).
- 01/12/2021
|
Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses
- CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2
- 12/22/2020
|
COCP Stock Price Increases 111.17% Over The Past Week: Why It Happened
- The stock price of Cocrystal Pharma, Inc. (NASDAQ: COCP) increased by 111.17% over the past week as it went from $0.90 per share on November 20 to $1.89 per share as of today. This is why it happened.
- 11/27/2020
|
Cocrystal Pharma: 8 Things for COCP Investors to Know About the Biotech Stock
- Cocrystal Pharma (COCP) is on the move Wednesday even with there being a lack of news concerning the pharmaceutical company. The post Cocrystal Pharma: 8 Things for COCP Investors to Know About the Biotech Stock appeared first on InvestorPlace.
- 11/25/2020
|
Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs
- – Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end –
- 11/16/2020
|
Cocrystal Pharma Selected to Present at the World Antiviral Conference
- BOTHELL, WA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Dr. Gary Wilcox and Dr. Sam Lee, have been selected to present at the World Antiviral Conference on Thursday, November 12, 2020 at 1:20 PM EST. The Company's presentation titled, “Antivirals against coronavirus and the A strains of the influenza virus,” will be accessible to those registered to attend the virtual event.
- 11/10/2020
|
Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
- – Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST –
- 11/06/2020
|
Cocrystal Pharma : Announces $10.0 Million Bought Deal Offering | MarketScreener
|
Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 08/18/2020
|
Turn $1 Into $2500 In 10 Years With 3x Bulls
- Weighted prices produce superior returns than calculations based on simple closing price. Neo-Classical Specter/FF5 with 6 buy signals, enhances returns and improves trend detection.
- 08/11/2020
|
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
- – COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviral agents progresses –BOTHELL, WA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced its financial results for the quarter ended June 30, 2020 and provided program updates.Recent Highlights * Expanded license with Kansas State University Research Foundation (“KSURF”) for rights to additional broad-spectrum antiviral compounds to treat Coronavirus infections. * Publication by collaborators of data demonstrating potent in vitro inhibition against Coronavirus in Science Translational Medicine Journal. * Appointed Roger D. Kornberg, Ph.D., a Nobel Laureate to its Board of Directors.“We have continued to move our antiviral programs forward. We are encouraged by our preclinical studies of COVID-19 inhibitors,” commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. “With a foundation of strong fundamentals, we believe Cocrystal is poised to build shareholder value.”Development Programs OverviewCOVID-19 Coronavirus Program: Aggressively pursuing the development of novel antiviral compounds for the treatment of coronavirus infections using our established proprietary drug discovery platform.The compounds licensed from KSURF have demonstrated in vitro anti-SARS-CoV-2 activity responsible for the COVID-19 pandemic, and in vivo efficacy in MERS-CoV-infected animal models. Cocrystal initiated its preclinical studies of COVID-19 inhibitors during the second quarter and is currently developing additional COVID-19 inhibitors utilizing its proprietary platform technology. The Company is in discussions with potential strategic partners.Influenza A/B Inhibitors: Merck Collaboration Exclusive license and collaboration agreement with Merck to discover and develop proprietary influenza A/B antiviral agents.Cocrystal’s exclusive license and collaboration agreement with Merck Sharp & Dohme Corp. (“Merck”) to discover and develop proprietary influenza A/B antiviral agents is ongoing. Merck has funded the collaborative influenza A/B program and could potentially provide up to $156 million in milestone payments as the collaboration proceeds through clinical and commercial development, plus royalties following commercialization. CC-42344: Influenza A Program: Novel, broad spectrum influenza antivirals that are specifically designed to be effective against pandemic and seasonal influenza A strains of the influenza virus and to have a high barrier to resistance due to its novel mechanism of action.The Company’s lead molecule in development, CC-42344, is currently being evaluated in IND-enabling studies for the treatment of influenza. CC-42344 has shown excellent antiviral activity against influenza A strains, including avian pandemic strains and Tamiflu® resistant strains, and shows a favorable pharmacokinetic and safety profile.CC-31244: Hepatitis C Program: Potential best-in-class pan-genotypic inhibitor of NS5B polymerase for the ultra-short combination treatment of hepatitis C infection.The final study report of Cocrystal’s U.S. Phase 2a clinical trial evaluating CC-31244 combination therapy for the ultrashort treatment of hepatitis C virus (“HCV”) infected individuals has been completed and confirms the previously released data that it is effective and well tolerated. Partnering efforts continue for the Company’s fully owned ultrashort treatment of HCV.Norovirus Program: Developing inhibitors targeting Norovirus RNA-dependent RNA polymerase and protease.Cocrystal continues to identify and develop non-nucleoside polymerase inhibitors using its proprietary structure-based drug design technology platform. Cocrystal recently entered into license agreements with KSURF to further develop proprietary broad-spectrum protease inhibitors to treat Norovirus and Coronavirus infections.Summary of Financial Results for Q2 2020As of June 30, 2020, Cocrystal had approximately $19,365,000 cash on hand.Revenue recorded for the three and six months ended June 30, 2020 was $554,000 and $1,015,000, respectively, compared with $592,000 and $5,670,000 for the three and six months ended June 30, 2019, respectively. The revenue for the six months ended June 30, 2019 included $4,368,000 as consideration in exchange for conveyance of intellectual property rights at the signing of the Merck Collaboration Agreement executed on January 2, 2019.General and administrative expenses for the three and six months ended June 30, 2020 was $2,028,000 and $3,167,000, respectively, compared with $1,051,000 and $2,374,000 for the three and six months ended June 30, 2019, respectively. The increase for the three and six months ended June 30, 2020 compared to the three months ended June 30, 2019 was primarily due to litigation costs, insurance increases and executive compensation.Total research and development expenses for the three and six months ended June 30, 2020 was $1,976,000 and $3,259,000, respectively, compared with $1,091,000 and $1,969,000 for the three and six months ended June 30, 2019, respectively. The increase for the three and six months ended June 30, 2020 compared to the three months ended June 30, 2019 was primarily due to increases in COVID-19 and Influenza programs.Net loss for the three and six months ended June 30, 2020 was $3,495,000 and $5,485,000, respectively, compared with a net loss of $1,515,000 and a net income of $1,456,000 for the three and six months ended June 30, 2019, respectively, as a result of revenue and expenses described above.About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to expected results of our collaboration with Merck, including the potential future milestone payments of up to $156,000,000 and royalties in connection with the collaboration; and the results of any partnering discussions relating to any of our programs. The words "believe," "proceeds," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from the impact of the COVID-19 pandemic on our Company, including supply chain disruptions, our continued ability to proceed with our programs, the national and global economy, our reliance on certain third parties, our reliance on continuing collaboration with Merck under the collaboration agreement, the future results of preclinical and clinical studies, general risks arising from clinical trials, receipt of regulatory approvals, development of effective treatments and/or vaccines by competitors. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2019, as updated and supplemented by the Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Additional factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.Investor and Media Contact: JTC Team, LLC (833) 475-8247 COCP@jtcir.com
- 08/06/2020
|
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
- 08/05/2020
|
Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal
- – Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus protease inhibitors (3CL) –BOTHELL, WA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the publication of preclinical animal studies of coronavirus antiviral compounds in the renowned medical journal, Science Translational Medicine.The manuscript titled, “The 3C-like protease inhibitors with potent in-vitro inhibition against SARS-CoV-2 and therapeutic efficacy in MERS-CoV infected mice,” was published online in the 3 August 2020 Science Translational Medicine Journal. Authors of the published manuscript were Athri D. Rathnayake, Jian Zheng, Yunjeong Kim, Krishani Dinali Perera, Samantha Mackin, David Meyerholz, Maithri M. Kashipathy, Kevin P. Battaile, Scott Lovell, Stanley Perlman, William C. Groutas, Kyeong-Ok Chang.Data presented in the publication is included in the Company’s two exclusive license agreements with Kansas State University Research Foundation (“KSURF”) for new coronavirus antiviral compounds with novel mechanism of action.“Our license agreement with KSURF has continued to exhibit the potential and broad utility of our platform to address the SARS-CoV-2 virus responsible for the COVID-19 worldwide pandemic. To have this compelling data included in the prestigious publication, Science Translational Medicine, is a testament to the potential of these inhibitors to treat COVID-19. The publication supports the quality and importance of the work performed by the group of co-authors,” commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal.Under the license agreements with KSURF, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans and small molecule therapeutic inhibitors against coronaviruses, picornaviruses and caliciviruses covered by patent rights controlled by KSURF. Cocrystal intends to continue development of these antiviral compounds for coronavirus. These licenses significantly expand and further advance the Company's COVID-19 program by providing more targeted and potent compounds.“We are incredibly enthusiastic with the positive preclinical data and the solid foundation we believe these inhibitors provide for advancing development of SARS-CoV-2 treatment,” added Dr. Sam Lee, President of Cocrystal. “The potent activity and the effectiveness of the mechanism of action demonstrated by these coronavirus protease inhibitors is very encouraging. Of utmost interest was the activity seen from a select number of compounds in the study series which were shown to be effective in vitro against SARS-CoV-2. In addition, we continue applying our proprietary platform technology to further optimize properties of lead molecules and are also exploring multiple routes of administration of these COVID-19 antivirals. These findings bolster our belief in the broad-spectrum capabilities and demonstrated proof-of-concept therapeutic efficacy of these inhibitors against human and animal coronaviruses.”Cocrystal initiated its preclinical studies of COVID-19 inhibitors received from KSURF during Q2 2020. The Company has also recently identified additional inhibitors using its proprietary platform technology and anticipates the selection of its lead preclinical molecule by year end.About Science Translational MedicineScience Translational Medicine is a weekly journal devoted to research and issues of strong interest to the translational medicine community. Translational medicine topics suitable for submission include any original research findings, discussions or analyses that move the field closer to the goal of improving human health, or the diagnosis and treatment of disease.Science Translational Medicine publishes original, peer-reviewed, science-based research articles that report successful advances toward the goal of improving patients' lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts hold Science Translational Medicine articles to the same high-quality standard that is the hallmark of the journal Science.About Coronavirus Disease 2019 (COVID-19)COVID-19 is caused by a coronavirus called SARS-CoV-2. Coronaviruses are a large family of viruses that are common in people and many different species of animals, including camels, cattle, cats, and bats. Rarely, animal coronaviruses can infect people and then spread between people. This occurred with MERS-CoV and SARS-CoV, and now with the virus that causes COVID-19.The virus that causes COVID-19 is thought to spread mainly from person to person, mainly through respiratory droplets produced when an infected person coughs or sneezes. These droplets can land in the mouths or noses of people who are nearby or possibly be inhaled into the lungs. Spread is more likely when people are in close contact with one another (within about 6 feet).COVID-19 seems to be spreading easily and sustainably in the community (“community spread”) in many affected geographic areas. Community spread means people have been infected with the virus in an area, including some who are not sure how or where they became infected.Summary updates are available on CDC’s web page: Coronavirus Disease 2019 (COVID-19).About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to expected results of our collaboration with Merck, including the potential of the Company’s platform to address the virus responsible for and treat COVID-19, the Company’s continued development of its licensed antiviral compounds ; and the anticipated timing of achieving the value-driving milestones in our COVID-19 program, including the selection of a preclinical lead molecule in Q4 2020. The words "believe," "proceeds," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from the impact of the COVID-19 pandemic on our Company, including (i) supply chain disruptions, (ii) our continued ability to proceed with our programs, and (iii) on the national and global economy, our reliance on certain third parties, and competition from major pharmaceutical and biotechnology companies which are advancing product candidates to treat COVID-19 and related vaccines. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2019. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Additional factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.Investor and Media Contact: JTC Team, LLC (833) 475-8247 COCP@jtcir.com
- 08/04/2020
|
Pressure mounts on NCP chairs to call Central Committee meet
- As many as 152 members of the Central Committee of Nepal Communist Party (NCP) on Wednesday wrote a letter to party co-chairpersons Pushpa Kamal Dahal and KP Sharma Oli demanding that a meeting of the Central Committee be held as soon as possible to discuss all issues that the party currently faces.
- 07/30/2020
|
Cocrystal Pharma (OTCMKTS:COCP) Shares Gap Down to $1.83
- Shares of Cocrystal Pharma Inc (OTCMKTS:COCP) gapped down before the market opened on Friday . The stock had previously closed at $1.87, but opened at $1.83. Cocrystal Pharma shares last traded at $1.83, with a volume of 3,702,200 shares changing hands. Several brokerages recently weighed in on COCP. Noble Financial began coverage on Cocrystal Pharma […]
- 07/12/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avadel Pharmaceuticals
- 07/08/2020
|
Top Stocks To Short As Dow Jumps Amid Coronavirus Spikes
- Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself. If you agree, it's not a bad time to take a few short positions.
- 07/06/2020
|
End jailing of minor drug offenders, says medical expert
- A UN epidemiologist claims prison environment not conducive to anti-Covid-19 measures.
- 07/02/2020
|
Ludhiana treatment plants: NGT asks Centre, state govt to release ₹36cr subsidy with 3 weeks
- The directive was given during the hearing of a petition filed by the Punjab Dyers Association against the delay in releasing the subsidy
- 06/30/2020
|
Dyadic International (DYAI) Receives a Buy from Noble Financial - Markets
- Noble Financial analyst Ahu Demir reiterated a Buy rating on Dyadic International (DYAI – Research Report) today and set a
- 06/29/2020
|
New Post From Your Neighbor
- This isn't meant to be nor should it be taken as a personal...
- 06/28/2020
|
New Post From Your Neighbor
- It's currently 2:00AM and very loud fireworks have been going...
- 06/27/2020
|
New Post From Your Neighbor
- 7:21
Friday evening.
- 06/27/2020
|
World Day Against Drug Abuse: UN Says, "Better Knowledge For Better Care"
- World drug abuse day 2020: Around 35.6 million people across the world are victims of drug abuse according to the World Drug Report 2020, which is published by the United Nations Office on Drugs and Crime. Young adults and teenagers account for the largest share of those using drugs and most of them suffer from HIV, Hepatitis C and other related diseases.
- 06/26/2020
|
New Post From Your Neighbor
- Fireworks have been being set off at night quite frequently...
- 06/25/2020
|
New Post From Your Neighbor
- Is there a rule / law in Skokie about fireworks/ fire crackers...
- 06/22/2020
|
New Post From Your Neighbor
- Seems like fireworks got started earlier this year. They seem...
- 06/22/2020
|
New Post From Your Neighbor
- Gary here with another local business recommendation. The...
- 06/19/2020
|
New Post From Your Neighbor
- Shootings in Skokie?
- 06/18/2020
|
5 Stocks To Hedge Your Portfolio With Instead Of Bitcoin
- The Nasdaq is within reach of all-time highs made last week. With the amount of fiscal and monetary stimulus on the table, and the economy seemingly rebounding from the lows, will it be enough to keep stock markets elevated? Our AI has identified the top stocks to short today.
- 06/18/2020
|
New Post From Your Neighbor
- I'm wondering if any other senior citizen (I am one)...
- 06/17/2020
|
New Post From Your Neighbor
- Anyone else experiencing a power outage?
- 06/16/2020
|
Crossbow thug terrorises street before spitting in cop's face amid gangland feud
- Darren Barr, who had Hepatitis C, was spotted marching up and down his street in Kirriemuir during lockdown after hearing that a revenge hit had been ordered on him by a gangland figure.
- 06/16/2020
|
New Post From Your Neighbor
- Great news! Skokie's Huntington Learning Center has re...
- 06/16/2020
|
Top Stocks To Short As Markets Continue To Fluctuate
- With the S&P 500, Nasdaq, and Dow going positive today, we believe the markets are overextended. Our deep learning and AI has identified several Top Shorts today for you to hedge your portfolio with or bet against overall.
- 06/15/2020
|
Don't Call Me Ethereum's Co-Founder Anymore, Says Cardano's Charles Hoskinson
- Charles Hoskinson, the co-founder of Input Output Hong Kong (IOHK), is getting increasingly upset for being associated with another project he co-founded
- 06/14/2020
|
World Blood Donor Day: 3 important reasons why donating blood is healthy
- It is vital to raise awareness about the health benefits of blood donation.
- 06/13/2020
|
Mengapa Tak Boleh Ada Aplikasi Alkitab Bahasa Minang di Indonesia yang Beragam?
- Gubernur Sumatera Barat mengatakan Alkitab berbahasa Minang tidak sesuai dengan budaya dan adat istiadat Minangkabau, padahal sudah diterjemahkan lebih dari 20 tahun lalu.
- 06/12/2020
|
Top Companies To Short As Stock Market Optimism Dips
- We have some buying this morning with markets recovering some of Thursday’s massive losses. However, it looks uneasy at best. For those looking to bet against the upward trend our AI technology paired with our deep learning algorithms have identified several Top Shorts today.
- 06/12/2020
|
New Post From Your Neighbor
- Is this an appropriate response to a request for a list of...
- 06/11/2020
|
New Post From Your Neighbor
- Why is there a right turn only lane on Niles Center going...
- 06/10/2020
|
Leading South Carolina Laboratory, Premier Medical Laboratory Services, Now Providing COVID-19 Antibody Testing
- Premier Medical Laboratory Services, a top commercial diagnostic laboratory is now expanding their COVID-19 testing portfolio by adding antibody testi
- 06/09/2020
|
Intrusion's New Product Could Be A Very Big Deal (OTCMKTS:INTZ)
- The company has introduced a new product called Shield, which is complementary to their existing products and mostly meant for the commercial market where Intru
- 06/05/2020
|
COVID-19: Gilead's Remdesivir Might Be As Good As It Gets (NASDAQ:GILD)
- Approved antiviral agents which might have a role in treating COVID-19 include Gilead’s remdesivir, Starpharma’s SPL7013; BioCryst Pharma’s Galidesivir; Pfizer
- 06/05/2020
|
Mesh Expands Presence to Austin
- One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
- 06/02/2020
|
COVID-19 Drug and Vaccine Pipeline Status Report - Research; Pre-Clinical; Phase 1, 2 & 3 Drug Candidates - ResearchAndMarkets.com
|
How Hedge Funds Traded Cocrystal Pharma, Inc. (COCP) During The Crash
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 05/28/2020
|
Gilead Sciences - The Overall Portfolio Has Never Been This Strong (NASDAQ:GILD)
- Gilead Sciences has recently advanced its work with Filgotinib while improving its oncology portfolio increasing the strength of its overall portfolio. The comp
- 05/28/2020
|
OPKO Health: A Hero Against The COVID-19 Villain But Has To Control Those Expenses Going Forward (NASDAQ:OPK)
- The company has been able to rapidly ramp up testing for COVID-19. Its revenue figures are down as sales of its other products have been affected by confinement
- 05/25/2020
|
Tracking David Einhorn's Portfolio - Q1 2020 Update (NASDAQ:GLRE)
- David Einhorn's 13F stock portfolio value decreased from $1.35B to $702M this quarter. Greenlight added Change Healthcare and increased CNX Resources while drop
- 05/23/2020
|
Foundry College Supporting Mental Health Awareness Week UK 2020 - The Wokingham Paper
- Last Friday, the primary and secondary students of Foundry College came together to create a range of artwork and posters in response to a shout out by Wokingham borough council, who asked pupils to support Mental Health Awareness Week UK 2020, by producing letters, postcards and drawings for isolated residents as part of goody bags or essential deliveries.
- 05/22/2020
|
Wolf's Corona Discounts: Bristol-Myers Squibb (NYSE:BMY)
- It's finally time to write about my favorite pharma stock in the corona-discount model. Bristol-Myers Squibb has gone from being a rather insignificant holding
- 05/19/2020
|
Locked up: Our round up of criminals jailed in Greater Manchester this week
- Here's what's happened in the courts this week
- 05/17/2020
|
Indonesia ikut "solidarity trial" vaksin COVID-19
- Indonesia telah mendaftar untuk mengikuti program uji coba global (solidarity trial) untuk vaksin COVID-19 yang dikoordinasi oleh Organisasi Kesehatan Dunia ...
- 05/16/2020
|
Why Cocrystal Pharma, Inc.'s (NASDAQ:COCP) CEO Pay Matters To You
- In 2016, Gary Wilcox was appointed CEO of Cocrystal Pharma, Inc. (NASDAQ:COCP). This report will, first, examine the...
- 05/15/2020
|
Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced its financial results for the quarter ended March 31, 2020 and provided program updates. Entered into license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections (“COVID-19”). Entered into additional license agreement with KSURF to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds for the treatment of coronavirus infections.
- 05/14/2020
|
Indian drug makers gear up to make Gilead's remdesivir for Covid-19 therapy
- Domestic players will be free to price it; Dutch firm Mylan also to make the drug in India; no royalty for Gilead as yet
- 05/13/2020
|
AHF Demands Gilead Price Remdesivir at $1.00 per Dose
- AHF Demands Gilead Price Remdesivir at $1.00 per Dose
- 05/12/2020
|
Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs
- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today provided an update on the impact of the COVID-19 global pandemic on its preclinical and clinical development programs. “We have reprioritized development activities to accelerate the advancement of our preclinical COVID-19 program, which we recently established as a result of our license agreements with Kansas State University Research Foundation (KSRF),” commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal.
- 05/11/2020
|
Gilead Sciences: Rapidly Building Up One Of The World's Best-Recognized Brands
- Gilead Sciences has an impressive portfolio of assets, but its brand is quickly becoming better known as a result of its COVID-19 drug. Outside of this, the com
- 05/07/2020
|
Gilead Sciences: Still A Core Holding
- I have held a significant position in Gilead which has served me well in recent weeks. Investors are fearful that Gilead might contribute to solving COVID-19 bu
- 05/02/2020
|
This Year's Tax-Loss-Selling Recovery Portfolio Is a Real Loser So Far
- This experiment in trying to identify stocks that could come back after dismal year-ago performance isn't going well five months since its inception.
- 05/01/2020
|
CMG, CLDX among premarket gainers
- SAExploration Holdings (NASDAQ:SAEX) +177% on $27M new project in Greece.B.O.S. Better Online Solutions (NASDAQ:BOSC) +56% on $1M order.The Peck Company Holdings (NASDAQ:PECK) +51% on partnership with
- 04/22/2020
|
Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action
- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that it has expanded its previously announced license agreement with Kansas State University Research Foundation (“KSURF”) to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds for the treatment of coronavirus infections (“COVID-19”). The additional compounds from this new license agreement represent a class of compounds called protease inhibitors to potentially treat COVID-19.
- 04/22/2020
|
Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors
- - Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of.
- 04/20/2020
|
MT, SSL among premarket losers
- Obalon Therapeutics (NASDAQ:OBLN) -25%.NeuroMetrix (NASDAQ:NURO) -16%.Cocrystal Pharma (NASDAQ:COCP) -14%.Covanta Holding (NYSE:CVA) -12% on dividend cut and guidance pull.Independence Contract Drilli
- 04/15/2020
|
Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit
- A live audio webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website (cocrystalpharma.com). Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
- 04/15/2020
|
Needed: A Master Plan for Covid-19 Patents
- Disputes over access to coronavirus treatments are already simmering. The Medicines Patent Pool could help everyone get access to the medicines they need.
- 04/10/2020
|
JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020
- Press Release JTC Team ("JTC") and LaVoieHealthScience ("LHS"), today announced their partnership to host the April 2020 Virtual Investor Summit on April 22nd and 23rd from 10:00 AM - 12:00 PM ET and 1:00 PM - 3:00 PM ET on both days. The Virtual Investor Summit will...
- 04/09/2020
|
JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020
- The Virtual Investor Summit features public and private companies from industries such as life sciences/biotech, infrastructure and transportation.
- 04/09/2020
|
Best free photography courses, apps and YouTube channels for lockdown learning
- How to emerge from self-isolation with new snapping skills
- 04/03/2020
|
Bay Area scientists forge alliance to stop coronavirus — it may prove key to cure
- Bay Area scientists, doctors and medical researchers are at the forefront, trying to unlock the secrets of the coronavirus, studying therapies and hastening toward a treatment or a cure. We talk with 10 of them.
- 04/03/2020
|
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
- Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration.
- 03/30/2020
|
Tax reforms for digital and multinational companies of 137 countries - CityAM
- At the Organisation for Economic Co-operation and Development’s (OECD) headquarters in Paris, negotiations are underway between 137 countries, on major
- 03/30/2020
|
How New York University Doctor Sharon Madanes Is Using Her Painting Studio to Create Urgent Reminders to Wash Your Hands
- The artist and physician shares how working in hospitals has changed her perceptions about art, and vice versa.
- 03/27/2020
|
Rare £20 notes: AA01 serial numbers could sell for £10,000
- New £20 notes with AA01 serial numbers as low as 000010 will be auctioned off next month and could sell for as much as £10,000.
- 03/13/2020
|
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
- The gross proceeds to the Company from the offering totaled approximately $6.8 million, before deducting placement agent fees and offering expenses. The shares of common stock described above were offered by Cocrystal Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-220632), which was previously declared effective by the Securities and Exchange Commission (“SEC”). A final prospectus supplement and the accompanying prospectus relating to the shares of common stock were filed by Cocrystal with the SEC and can be obtained at the SEC’s website at www.sec.gov.
- 03/11/2020
|
Company News for Mar 10, 2020
- Companies In The News Are: COCP, CGEN, AAPL, NINE
- 03/10/2020
|
Company News for Mar 10, 2020
- Companies In The News Are: COCP, CGEN, AAPL, NINE
- 03/10/2020
|
Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market
- H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the Securities and Exchange Commission (SEC). A final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.
- 03/09/2020
|
Mid-Afternoon Market Update: Dow Tumbles 8%; AIM ImmunoTech Shares Spikes Higher
- Toward the end of trading Monday, the Dow traded down 8% to 23794.55 while the NASDAQ fell 6.95% to 7,979.78. The S&P also fell, dropping 7.71% to 2,743.27. Coronavirus cases...
- 03/09/2020
|
Mid-Day Market Update: Dow Falls 1400 Points; Matador Resources Shares Plunge
- Midway through trading Monday, the Dow traded down 5.43% to 24,461 while the NASDAQ fell 4.35% to 8,202.44. The S&P also fell, dropping 5.03% to 2822.74. Coronavirus cases...
- 03/09/2020
|
101 Stocks Moving In Monday's Mid-Day Session
- Gainers
Spherix Incorporated (NASDAQ: SPEX) shares jumped 139% to $3.92 after jumping 131% on Friday.
AIM ImmunoTech Inc. (NYSE: AIM) shares jumped 63.1% to $3.43 amid the...
- 03/09/2020
|
Cocrystal Pharma Announces Plans to Advance Coronavirus Program
- Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial.
- 03/06/2020
|
NVAX, INO among premarket gainers
- Digirad (NASDAQ:DRAD) +63% on Q4 results.Enzo Biochem (NYSE:ENZ) +50% on launch of coronavirus testing service.NanoViricides (NYSEMKT:NNVC) +34% on coronavirus drug progress.TEGNA (NYSE:TGNA) +28% on
- 03/06/2020
|
CVS, UNH among premarket gainers
- Cellect Biotechnology (NASDAQ:APOP) +38% on Canndoc deal.Dynatronics (NASDAQ:DYNT) +28%.AIM ImmunoTech (NYSEMKT:AIM) +24% on recent announcements on Covid-19 front.Arcturus Therapeutics Holdings (NASD
- 03/04/2020
|
Coronavirus plays - vaccines, drugs & infection control products
- Below are companies that have announced plans to develop either vaccines or therapies for COVID-19. Again, some are more credible than others.Vaccines: Sanofi (SNY -1.5%), iBio (IBIO -10.2%), Vaxart (
- 03/03/2020
|
An overview of this week's golf tournaments around the world
- PGA TOUR ARNOLD PALMER INVITATIONAL Site: Orlando, Fla.
- 03/03/2020
|
Healthcare dominates premarket losers amidst coronavirus situation
- Spherix (NASDAQ:SPEX) -25%.Dynatronics (NASDAQ:DYNT) -22%.China Pharma Holdings (NYSEMKT:CPHI) -19%.Co-Diagnostics (NASDAQ:CODX) -17%.Tilray (NASDAQ:TLRY) -14% on Q4 earnings.Cleveland BioLabs (NASDAQ
- 03/03/2020
|
TSLA, TWTR among premarket gainers
- Daxor (NYSEMKT:DXR) +77% on coronavirus news.Forty Seven (NASDAQ:FTSV) +62% as Gilead Sciences makes $95.50 per share cash offer.Trillium Therapeutics (NASDAQ:TRIL) +51% as Gilead Sciences makes $95.5
- 03/02/2020
|
Stocks To Watch: Time For Coronavirus Offense Or Defense?
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 02/29/2020
|
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced registered direct offering with several institutional investors for 8,461,540 shares of its common stock at a purchase price of $1.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $11.0 million, before deducting placement agent fees and offering expenses. The shares of common stock described above were offered by Cocrystal Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-220632), which was previously declared effective by the Securities and Exchange Commission (“SEC”).
- 02/28/2020
|
NVAX, SGMO among premarket gainers
- Dynatronics (NASDAQ:DYNT) +224%.Altimmune (NASDAQ:ALT) +143% on completing first development milestone toward a single-dose intranasal COVID-19 vaccine.Allied Healthcare Products (NASDAQ:AHPI) +103% a
- 02/28/2020
|
WLL, SPEX, CODX and AIM among midday movers
- Gainers: iBio (NYSEMKT:IBIO) +131%.GAIN Capital Holdings (NYSE:GCAP) +66%.Vaxart (NASDAQ:VXRT) +57%.Co-Diagnostics (NASDAQ:CODX) +55%.Vir Biotechnology (NASDAQ:VIR) +51%.Allied Healthcare Products (NA
- 02/27/2020
|
ABEV, PLAN among premarket losers
- Anaplan (NYSE:PLAN) -29% despite Q4 beat.Continental Resources (NYSE:CLR) -26% on Q4 earnings.Nutanix (NASDAQ:NTNX) -20% on Q2 earnings.Virgin Galactic Holdings (NYSE:SPCE) -18% after pair of Wall Str
- 02/27/2020
|
Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market
- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,461,540 shares of its common stock at a price of $1.30 per share, for aggregate gross proceeds of approximately $11.0 million, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the Securities and Exchange Commission (SEC).
- 02/27/2020
|
TOL, SDC among premarket losers
- SmileDirectClub (NASDAQ:SDC) -24% on Q4 earnings.Spherix (NASDAQ:SPEX) -22%.Fossil Group (NASDAQ:FOSL) -20% on Q4 earnings.Menlo Therapeutics (NASDAQ:MNLO) -19% after chronic pruritus Phase 2 trial fa
- 02/26/2020
|
80 Biggest Movers From Yesterday
- Gainers
Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 77.4% to close at $5.80 on Tuesday.
Cocrystal Pharma Inc (NASDAQ: COCP) shares surged 64.7% to close at $2.19 on...
- 02/26/2020
|
18 Medical Stocks To Watch Amid The Coronavirus Outbreak
- Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries
- 02/25/2020
|
55 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
Cocrystal Pharma Inc (NASDAQ: COCP) climbed 79% to $2.38 S
Mallinckrodt plc (NYSE: MNK) climbed 33.6% to $5.57 after the company announced a global opioid settlement...
- 02/25/2020
|
NIO, FCEL among premarket gainers
- VivoPower International PLC (NASDAQ:VVPR) +57% on 1H results.Cocrystal Pharma (NASDAQ:COCP) +54%.Mallinckrodt plc (NYSE:MNK) +38% on Q4 results and global opioid settlement.NIO (NYSE:NIO) +34% after i
- 02/25/2020
|
Mid-Afternoon Market Update: Dow Dips 950 Points; Carter's Shares Fall On Earnings Miss
- Toward the end of trading Monday, the Dow traded down 3.28% to 28042 while the NASDAQ fell 3.59% to 9232.86. The S&P also fell, dropping 3.17% to 3232.07.
Leading and Lagging...
- 02/24/2020
|
Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds
- BOTHELL, WA, Feb. 24, 2020 -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used.
- 02/24/2020
|
Nanocap Biotech Stock Rips 180% Higher On Coronavirus Drug Licensing
- Cocrystal Pharma Inc (NASDAQ: COCP) shares are skyrocketing Monday following a licensing agreement the company reached with the Kansas State University Research Foundation....
- 02/24/2020
|
Rural communities face HIV outbreak risk due to lack of syringe exchanges
- It's another ripple effect of the opioid epidemic.
- 02/18/2020
|
Those Who Purchased Cocrystal Pharma (NASDAQ:COCP) Shares Five Years Ago Have A 98% Loss To Show For It
- Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
- 02/17/2020
|
Bericht: Sion - Xamax, 15. Februar 2020 - Blick
- Sion-Captain Kouassi könnte schon in der Startphase mit Rot fliegen – und tut das dann in Minute 55 doch noch. Zehn Walliser verlieren auch gegen Xamax. 1:2.
- 02/15/2020
|
Cocrystal Pharma Inc.’s Structure-Based Technology has Demonstrated Broad Utility in Development of Antivirals
- – Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address.
- 02/13/2020
|
Utah cuts healthcare costs by flying employees to Mexico for prescriptions
- Utah’s plan lets people collect medications at a fraction of the US cost, while other states are looking to import drugs from Canada
- 02/11/2020
|
Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
- – Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical.
- 02/11/2020
|
COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING
- BOTHELL, WA, Feb. 03, 2020 -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel.
- 02/03/2020
|
The Wuhan Coronavirus: 21 Stocks to Watch
- News like the Coronavirus can affect the stock market — either as a whole or just certain stocks and sectors. See how you can prepare.
- 01/29/2020
|
COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING
- The Company intends to use the net proceeds for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the SEC.
- 01/29/2020
|
Why I built a diagnostic centre for my community – Dr. Sabo Tanimu
- Dr. Sabo Tanimu is Founder and President, Tanimu Foundation. He has a strong passion for philanthropy having grown in an environment where he saw people in dire need. A 1995 graduate of Ahmadu Bell…
- 01/04/2020
|
World's first cloned cat celebrates 18th birthday baffling scientists
- Copy Cat was the first animal to ever be cloned back in 2001 at Texas A&M University and is now living a healthy life
- 01/03/2020
|
Junqueras’ political rights
- The dissenting votes from three CC judges are proof that the Supreme Court acted in a questionable manner
- 12/18/2019
|
Golf Glance
- EUROPEAN TOUR AND PGA TOUR OF AUSTRALASIA AUSTRALIAN PGA CHAMPIONSHIP Site: Gold Coast, Australia.
- 12/17/2019
|
Lancashire CC fixtures 2020: Red Rose to play all home County Championship matches at Old Trafford
- Date of Lancashire v Yorkshire T20 fixture and schedule for The Hundred revealed
- 11/26/2019
|
Today's health problems are tomorrow's health crises
- Rising obesity rates will strain the most expensive health care system in the world.
- 10/31/2019
|
Lincs cricketer to play alongside Joe Root and Rashid Khan in The Hundred
- The Trent Rockets met his £60,000 asking price
- 10/21/2019
|
Procedure For Self Redevelopment Of Housing Societies In Maharashtra - Accommodation Times
- By Dr Sanjay Chaturvedi, LLB, PhD Builders are not finding viable projects offered by housing societies in Maharashtra, are going in for self redevelopment. Due to slow down in market and new DCR where the redevelopment is not viable in Mumbai, housing societies in Maharashtra are going in for self redevelopment. Developing a residential project...
- 10/19/2019
|
Sale of Member’s Interest and Claims on Loan Account Agreement with a Restraint of Trade (underlying asset is a business)
- Moneyweb Insider Gold subscribers receive 12.5% discount! EXPLANATORY NOTES: AGREEMENT FOR THE SALE OF A MEMBER’S INTEREST AND CLAIMS ON LOAN ACCOUNT IN A CLOSE CORPORATION WHERE THE PURCHASER IS NOT A MEMBER AND WHERE THE CC OWNS A BUSINESS, BUT NO IMMOVABLE PROPERTY. A RESTRAINT OF TRADE IS INCLUDED. This is a very detailed agreement that may be used where a member in a close corporation is selling his/her member’s interest and claims on loan account in a close corporation to a party who is not a member of the CC. This agreement is for use solely where the CC owns a business. The agreement is drafted to cater for a situation where there are remaining members in the CC and also where there are no remaining current members. Detailed drafting notes assist with making the necessary changes. This agreement is for use where the CC owns an underlying business and includes a restraint of trade to protect the purchaser. NOTE: this is an agreement for the sale of a member’s interest and claims only and NOT for the sale of a business. HOWEVER, as we assume that this agreement caters for a situation where the underlying CC owns a business, this agreement requires that the seller provide the purchaser with certain undertakings in respect of the business as well as the member’s interest and the claims on loan account. This agreement is subject to suspensive conditions. Please pay attention to our extensive drafting notes in the agreement regarding suspensive conditions. Moneyweb Readers: R 800.00 incl VAT Moneyweb Insider Gold subscribers: R 700.00 incl VAT
- 08/20/2019
|
10 best CC creams that help conceal, colour correct and reduce redness
- Target discolouration and treat uneven skin tones with a multi-tasking make-up product
- 05/28/2019
|
Ogden needle-exchange program for drug users on hold due to police concerns
- OGDEN — Plans to launch a needle-exchange program in Ogden for drug users have been put on hold, at least temporarily, due to questions and concerns from local law enforcement
- 03/30/2017
|
Nanoviricides (NNVC) Target a Plethora of Viruses
- In previous articles we have discussed the potential of nanotechnology enabled drug delivery systems such as those offered by Bind Therapeutics. We also noted that companies such as SkyePharma and Flamel were discussed as having potential but neither company has succeeded yet in launching a blockbuster nanotechnology drug. More importantly, we have highlighted the fact that over-the-counter companies often use the word 'nano' in an attempt to gain credibility with investors often leading to disastrous results. One company that recently began trading on the NYSE Marketplace is Nanoviricides. About NanoViricides, Inc. (NYSEMKT:NNVC) was incorporated under the laws of
- 10/30/2013
|
